Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642964 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Chase Therapeutics Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03642964: Active Phase 2 study of Major Depressive Disorder (MDD), sponsored by Chase Therapeutics Corporation.
NCT03642964 is a Phase 2 study of Major Depressive Disorder (MDD) that is active but no longer recruiting, run by Chase Therapeutics Corporation. The registered enrollment target is 24 participants, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03642964, a Phase 2 study of Major Depressive Disorder (MDD), is active but no longer recruiting, sponsored by Chase Therapeutics Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
Conditions Studied
Interventions
- DRUG CTC-501
Study Locations (1)
California
- Collaborative Neuroscience Network - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
What the registry record for NCT03642964 still lists
NCT03642964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which CTC-501 is the first listed.
NCT03642964 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03642964 about?
NCT03642964 is a clinical study titled "A Study in Patients With Major Depressive Disorder". This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
What is the current status of trial NCT03642964?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-09-10. Estimated completion is 2025-12-30.
What conditions does trial NCT03642964 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT03642964?
The interventions under investigation include: CTC-501 (DRUG).
Who is sponsoring clinical trial NCT03642964?
This trial is sponsored by Chase Therapeutics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03642964 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03642964's enrollment target sits among peer trials
24 19th of 22 higher than 3 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI